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Measuring Somatic Symptoms With the CES–D to Assess
Depression in Cancer Patients After Treatment: Comparison
Among Patients With Oral/Oropharyngeal, Gynecological,
Colorectal, and Breast Cancer
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R.E. STEWART, M.SC., A.V. RANCHOR, M.SC., PH.D.
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There is a high prevalence of depression after cancer treatment. In the literature, several authors
have raised questions about assessing somatic symptoms to explore depression after cancer treat-
ment. These somatic sequelae are a consequence of cancer treatment and should cause higher
depression rates in cancer patients. In this study, the Somatic domain on a depression question-
naire, the Center for Epidemiologic Studies–Depression scale (CES–D) was analyzed in different
cancer patients after treatment, as compared with a control group. Data from 566 cancer pa-
tients (oral/oropharyngeal, gynecological, colorectal, and breast cancer) and 255 randomly cho-
sen comparison patients were analyzed. The total score on the CES–D domain of Somatic Re-
tarded Activity significantly differed between the cancer and comparison groups; but the cancer
groups showed both less somatic morbidity (colorectal cancer) and more somatic morbidity
(oral/oropharyngeal, breast) than the comparison group. In the analyses of the CES–D with and
without the Somatic domain, the prevalence of depression symptoms with the Somatic domain is
lower for the cancer groups. Authors conclude that cancer patients are not a homogenous group
as regards somatic sequelae. Evidence for removing Somatic items from the CES–D for patients
after cancer treatment was not confirmed. (Psychosomatics 2006; 47:465–470)
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Survival rates of several cancer types have increasedbecause of earlier detection and better treatment ap-
proaches.1 As a consequence, more patients have to cope
with the physical and emotional consequences of the di-
agnosis of cancer and the side effects of treatment. In the
last decade, more attention has been given to this group of
patients. Important in posttreatment cancer research are
quality of life,2 coping,3,4 depression,5,6 somatic morbid-
ity,7,8 pain,9–11 and fatigue.12,13 This research has led to a
better understanding of physical and emotional problems
after cancer treatment, and, as a consequence, treatment
programs have been developed, such as: post-cancer treat-
ment rehabilitation programs,14 psychosocial interven-
tions,15,16 pain management,10 and multidisciplinary pro-
grams.17
A major important outcome after cancer treatment is
depression. The prevalence of depression after cancer treat-
ment is about 24% (range: 1.5% to 50%).18 Depression
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affects quality of life, survival, length of hospital stay, and
therapy compliance.5,18,19 It is therefore clinically impor-
tant to recognize depression in the posttreatment phase of
cancer patients. Physicians are often not well trained in
recognizing depression;20 therefore, a questionnaire is
helpful for exploring depression symptoms during the
medical follow-up.
According to DSM-IV, a depressive episode is as-
sumed if five (or more) out of nine symptoms (see Appen-
dix 1) are present; also, the symptoms should be present
during the same 2-week period and represent a change
from previous functioning.21 Symptoms of a clinical de-
pression in patients after cancer treatment can be assessed
through a clinical interview, a (semi)-standardized inter-
view, or a questionnaire. Questionnaires are most fre-
quently used in the medical setting and for clinical cancer
research.
The prevalence of depression in cancer patients is re-
lated to type of cancer, follow-up, medical illness, gender,
and method of assessment.18,19,22,23 Several authors have
also suggested that the high prevalence of depression after
cancer treatment is due to the fact that the somatic symp-
toms of depression are similar to the somatic symptoms
caused by the cancer treatment, itself.6,22,24,25 They state
that somatic symptoms should not be measured when as-
sessing depression in cancer patients. Some authors have
even removed somatic items from depression question-
naires,24,25 and, in the Hospital Anxiety and Depression
Scale (HADS), somatic symptoms are not even included
in the depression scale.26
Hard evidence for the hypothesis that somatic symp-
toms should be removed in a depression questionnaire
when assessing cancer patients is virtually missing, al-
though some studies have been performed to explore this
hypothesis. In one study exploring the role of somatic items
in cancer patients, the Zung Self-Rating scale was divided
into a questionnaire with and without somatic items. The
outcome on the questionnaire with somatic items was about
5% higher. The authors stated that the Zung Self-Rating
scale has 5% more false-positive depressed cancer patients
when somatic items are included.24 After a factor analyses
of the Zung Self-Rating depression scale, Passik et al.27
found that fatigue is the only somatic item that is typically
a symptom of depression in cancer patients; this is in con-
trast with the results of Visser and Smets,25 who found no
relationship between depression and fatigue. They stated
that fatigue is not a valid criterion for depression for pa-
tients after radiation therapy. After analyzing a structured
interview with cancer patients Akechi et al.28 found that
eating disorders and concentration problems were strongly
related to depression, whereas sleep disorders and fatigue
were related to the somatic sequelae of cancer treatment.28
During radiotherapy in oral and oropharyngeal cancer pa-
tients, several eating-related side effects are described,
which affect the outcome of depression questionnaires.29,30
From these studies, no clear conclusion can be made about
the role of somatic items in the assessment of depression
in cancer patients.
From the above, it is clear that the prevalence of de-
pression in cancer patients is high, and there is concern
about a potential similarity of the somatic symptoms
caused by cancer treatment and those caused by depres-
sion; these similarities may increase the percentages of
false-positive depression findings assessed with a question-
naire when somatic items are included. The aim of this
study was to analyze the influence of somatic symptoms
on the CES–D in cancer patients after treatment, as com-
pared with a control group, and to analyze this influence
between cancer types.
METHOD
The CES–D is a short self-report scale designed to measure
depressive symptoms.31 The questionnaire was translated
into Dutch; it contains 20 items, divided in four domains:
Somatic Retarded Activity (7 items), Depressed Affect (5
items), Positive Affect (4 items), and Interpersonal Affect
(2 items), and 2 single items that complete the total
score.32,33 The total score ranges from 0 to 60; a score of
 16 indicates a depressed symptomatology. The CES–D
is often administered to inpatients with cancer. The CES–
D in cancer patients has a good internal consistency (
0.89) and the test–retest reliability was 0.51 (p 0.001).
The construct validity and internal consistency of the CES–
D are good.32 The positive predictive value is 54.5% for
the cut-off score of 16 in head and neck cancer patients.34
The CES–D is appropriate for use in clinical psychosocial
research.35
In the current study, the CES–D was administered to
patients at least 1 year after the first cancer treatment (and
to a control group). Patients with tumor recurrences were
excluded.
The data of comparison subjects and patients with
breast, colorectal, and gynecological cancer were obtained
from the database of the Northern Centre for Health Care
Research (NCG).36 The comparison group was matched for
gender and age with the cancer group and lived in the same
area as the patients with cancer. Patients with oral/oropha-
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ryngeal cancer were assessed in the University Hospital,
Groningen, in the Department of Oral and Maxillofacial
Surgery; the Department of Otorhinolaryngology, Head,
and Neck Surgery; or the Department of Surgical Oncol-
ogy. The CES–D was assessed during a regular appoint-
ment in the outpatient clinic. Patients received a letter 1
week before their appointment, in which the study was
explained. Their medical doctor asked the patients to par-
ticipate. If patients were willing to participate, an in-
formed-consent was signed, and the CES–D was filled out.
The Review Board of the hospital approved the study.
Statistical Analysis
For the statistical analysis, we used SPSS 10.0. We
tabulated descriptive data (gender, age, treatment, depres-
sion symptoms); relative risk (RR) and 95% confidence
intervals (CI) were calculated with the CIA (Confidence
Interval Analyses, 2nd Version). The CES–D total scores,
Somatic Retarded Activity scores, and the Depressed Af-
fect scores were also calculated. The comparison and the
cancer groups were compared on the CES–D total, and the
domains of Somatic Retarded Activity and Depressed Af-
fect were compared by ANOVA. Also, a multi-comparison
was performed among the control group and four cancer
groups on the CES–D total, and the domains of Somatic
Retarded Activity and Depressed Affect, with a Bonferroni
post-hoc correction. We performed a Kruskal-Wallis test as
control for the outcome on the ANOVA multi-comparison
tests because the outcomes on the CES–D were not nor-
mally distributed.
Correlations (Spearman q) between the domains of
Somatic Retarded Activity and Depressed Affect were an-
alyzed for the comparison group and cancer patients. A
new cut-off point for depressed symptoms was calculated
for the CES–D without the Somatic items, as previously
described with the Zung depression scale.24 If a patient had
a score of  16, in the 20-item version, there is an indi-
cation of depression symptoms (16/20, or 0.8). Therefore
the new cut-off point for the 13-item version is 10 (0.8
13 [without Somatic items]) 10.4).
We used the McNemar test to compare the CES–D
with and without the Somatic items.
RESULTS
In this cross-sectional study with reference-group data, we
analyzed data from 509 patients and 223 randomly chosen
comparison subjects. Descriptive data are presented in Ta-
ble 1. The breast and gynecological cancer patients were
typically women. Patients with depression symptoms, ac-
cording to the CES–D, are listed in Table 1. The prevalence
of depression symptoms in the cancer groups was 16%
(oral/oropharyngeal), 22% (breast cancer), and 23% (gy-
necological group); this is a bit lower than reported in the
literature, and the prevalence for colorectal cancer was sur-
prisingly low, at 7%. In Table 2, the results of the ANOVA
between groups are presented. The cancer group scored
significantly higher than the control group on the domain
of Somatic Retarded Activity and Depressed Affect. The
four cancer groups and the comparison group differ sig-
nificantly on Total score, Somatic Retarded Activity, and
Depressed Affect scores (Table 2). In the ranking of the
Kruskal-Wallis (not presented in the table) the colorectal
patients scored the lowest on all scales. Oral/oropharyngeal
patients and breast cancer patients scored highest for So-
matic Retarded Activity. The Total score, the Somatic Re-
tarded Activity score and Depressed Affect score were sig-
nificantly (p 0.01) different for the cancer groups and
comparison group. The outcomes on the Kruskal-Wallis
test were similar to the outcome on the ANOVA multi-
comparison analysis. The correlations between the do-
mains of Somatic Retarded Activity and Depressed Affect
were significant for the control group (0.54; p 0.01) and
the cancer group (0.66; p 0.01).
The CES–D with and without depression symptoms
and with and without the somatic items are presented in
Table 3. The cancer groups, except the oral/oropharyngeal
patients, and comparison group showed significantly
higher incidences of depression symptoms without the So-
matic items, as compared with the CES–D with Somatic
items.
DISCUSSION
Cancer patients are not a homogeneous group with respect
to the outcome of the CES–D and the domains of Somatic
Retarded Activity and Depressed Affect. As compared with
a control group, cancer patients score lower (colorectal) as
well as higher (breast, oral/oropharyngeal) on the domain
of Somatic Retarded Activity. Somatic sequelae for each
type of cancer differ, and, therefore, “the cancer patient”
does not exist. After removing the Somatic items of the
CES–D to assess depression in cancer patients, the per-
centages of patients with depression symptoms increases.
The hypothesis that the prevalence of false-positive de-
pression increases when Somatic items are included in the
CES–D could not be verified in the current study. The cor-
Measuring Somatic/Depression Symptoms
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TABLE 1. Descriptive Data (Gender, Age) of the Control Group, Cancer Patients, and Cancer Subgroups, Type of Treatment, and














N 223 509 189 104 62 154
Female gender 70% (155) 67% (340) 99% (188) 38% (40) 100% (62) 33% (50)
Age, years, mean (SD) 57 (15) 59 (14) 55 (13) 65 (12) 54 (16) 61 (12)
Surgery — 99% (504) 98% (186) 100% (104) 97% (60) 100% (154)
Radiation therapy — 48% (245) 54% (102) 11% (11) 42% (26) 69% (106)
Chemotherapy — 19% (99) 42% (80) 7% (7) 19% (12) 0% (0)
Depressive symptomatologya 10% (23) 17% (87) 22% (41) 7% (7) 23% (14) 16% (25)
Relative risk b (95% CI) 1.00 1.66 (1.08–2.55) 2.10 (1.31–3.37) 0.65 (0.29–1.47) 2.19 (1.20–3.00) 1.57 (0.91–2.67)
Values are percent (N), unless otherwise noted. Relative risks, 95% confidence intervals of depressed symptomatology, are presented for the cancer
patients and the cancer subgroups. CI: confidence interval.
aCES–D score 16.
bThe control group is the reference group.
CES–D: Center for Epidemiological Studies–Depression scale.
TABLE 2. Scores on the CES–D Total, the Domains of Somatic Retarded Activity (7 items), and Depressed Affect (5 items)
CES–D Total p Somatic Retarded p Depressed Affect p
Cancer group total 9.0 (8.5) 0.26 3.0 (3.4) 0.006 1.6 (2.5) 0.001
Control group (C) 8.3 (6.4) 2.3 (2.6) 0.9 (1.7)
Breast (B) 10.5 (8.3) 3.3 (3.2) 1.9 (2.6)
Colorectal (CR) 7.0 (6.7) 1.7 (2.4) 0.9 (1.8)
Gynecological (G) 9.4 (9.6) 2.6 (3.5) 1.9 (3.0)
Oral and oropharyngeal (O) 8.3 (8.9) 0.002 3.8 (4.0) 0.001 1.5 (2.4) 0.001
Presented are the ANOVA for comparisons between groups (control versus cancer) and an ANOVA with multiple comparison (with Bonferroni
correction) between the control and four cancer subgroups.In the multiple corrected comparisons, significant differences (p0.05) were found for the
following domains: CES–D Total: C–B, B–CR; Somatic Retarded: C–B, C–O, B–CR, CR–O; and Depressed Affect: C–B, C–G, B–CR, CR–G.
CES–D: Center for Epidemiological Studies–Depression scale.





Without Somatic Domain p
No Yes
Control N223 No 172 (77%) 23 (10%) 0.001
Yes 0 (0%) 28 (13%)
Breast N189 No 125 (66%) 21(11%) 0.001
Yes 4 (2%) 39 (21%)
Colorectal N104 No 87 (84%) 10 (10%) 0.012
Yes 1 (1%) 6 (6%)
Gynecological N62 No 42 (68%) 6 (10%) 0.031
Yes 0 (0%) 14 (23%)
Oral and oropharyngeal N154 No 124 (81%) 5 (3%) 0.453
Yes 2 (1%) 23 (15%)
A McNemar test was performed to analyze the influence of the Somatic items on the CES–D for the four cancer groups and control group.
Percentages are cell percentages.
CES–D: Center for Epidemiological Studies–Depression scale.
van Wilgen et al.
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relation between Somatic items and the Depressed Affect
items is considerable, indicating that the domains were in-
terrelated and, as in the construct of depression, cannot be
separated.
The influence of gender on outcome of depression
questionnaires is known to be significant.37 The patients
with breast and gynecological cancer were predominantly
women, and the percentages of patients with depression
symptoms and the scores on the domain of Depressed Af-
fect are the highest in these two cancer groups. Whether
these high scores are the effect of cancer type, female gen-
der, or both cannot be distinguished in this study. In con-
trast, oral/oropharyngeal patients score significantly higher
on the Somatic Retarded Activity domain. Oral/oropharyn-
geal cancer surgery is often extensive surgery, leading to
considerable morbidity, often followed by radiation ther-
apy, which may explain the high scores on the Somatic
Retarded Activity scale. Patients after colorectal cancer
therapy score lower on all outcomes; the number of female
patients in this group is low, and the number of patients
with double treatment, for instance, surgery and radiation
therapy, is also lower. Receiving two treatment modalities
might affect the prevalence of depression, and this might
be an interesting topic for further studies.
In the current study, somatic morbidity does not in-
crease the prevalence of depression symptoms as measured
with the CES–D; on the contrary—depression symptoms
were more frequently present without the Somatic items.
This is in contrast with the study of Dugan et al.,24 who
analyzed the Zung Self-Rating depression scale with and
without somatic items, reporting 5% more false-positives
when measuring depression symptoms with somatic items.
It would be valuable in further studies to compare sev-
eral depression questionnaires on the influence of the so-
matic items because it seems that the impact of the somatic
items differs among the questionnaires.
This study included a large and varied sample of can-
cer patients and a reference group, and, therefore, the re-
sults of this study seem generalizable to clinical settings.
In further research, these findings must be confirmed in
prospective studies.
A limitation of the study was that it applied a cross-
sectional design and that no external criterion for depres-
sion was used—for instance, a standard psychiatric inter-
view.
In conclusion, the use of questionnaires to assess de-
pression symptoms in the medical setting is valuable be-
cause of the high prevalence of depression to be found
there. The incidences of somatic morbidity within cancer
types differs, but somatic items do not interfere with the
outcome of depression as measured with the CES–D. The
CES–D seems accurate in measuring depression in cancer
patients and appears to be useful in clinical practice.
This study was supported by a grant from the Univer-
sity Hospital Groningen, the Netherlands.
APPENDIX 1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria for Depression
1. depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad or empty) or observation made by
others
2. markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day
3. significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body weight in a month), or decrease or increase in
appetite nearly every day
4. insomnia or hypersomnia nearly every day
5. psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed
down)
6. fatigue or loss of energy nearly every day
7. feelings of worthlessness or excessive or inappropriate guilt
8. diminished ability to think or concentrate, or indecisiveness, nearly every day
9. recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for
committing suicide
Furthermore:
The symptoms do not meet criteria for a mixed episode.
The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse; a medication) or a general-medical condition
(e.g., hypothyroidism).
The symptoms are not better accounted for by bereavement (i.e., after the loss of a loved one, the symptoms persist for longer than 2 months or
are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or
psychomotor retardation).
Measuring Somatic/Depression Symptoms
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